Gilead reported FY 2025 total revenues of USD 29.4 billion (+2%) and net income attributable to shareholders of USD 8.5 billion, with diluted EPS of USD 6.78. Product sales were USD 28.9 billion (+1%), supported by HIV sales of USD 20.8 billion (+6%) and Liver Disease sales of USD 3.2 billion (+6%), while Veklury sales were USD 911 million (-49%) amid lower COVID-19-related hospitalizations. Oncology sales were USD 3.2 billion (-2%), including Cell Therapy sales of USD 1.8 billion (-7%) and Trodelvy sales of USD 1.4 billion (+6%). FY 2025 R&D expense was USD 5.8 billion (-2%) and SG&A was USD 5.8 billion (-5%); acquired in-process R&D expense was USD 1.0 billion (-78%), and in-process R&D impairments were USD 590 million (-86%). Cash and cash equivalents were USD 7.6 billion at Dec. 31, 2025, and Gilead recorded FY 2025 operating cash flow of USD 10.0 billion (-7%); the company paid USD 4.0 billion in dividends, repurchased USD 1.9 billion of common stock, and repaid USD 1.8 billion of debt during FY 2025. Business highlights for FY 2025 included U.S. FDA approval of Yeztugo (lenacapavir) for HIV PrEP and European Commission marketing authorization for Yeytuo for PrEP, along with a CDC guideline recommendation for twice-yearly injectable lenacapavir for PrEP. Gilead also announced settlement agreements in Biktarvy U.S. patent litigation that set April 1, 2036 as the earliest date certain generic manufacturers can launch a full-dose generic, and disclosed an FDA clinical hold on HIV treatment trials of GS-1720 and/or GS-4182 (including WONDERS-1 and WONDERS-2). In oncology, Gilead entered into a definitive agreement to acquire Arcellx (expected to close in Q2 2026), discontinued the Phase 3 STAR-221 and Phase 2 EDGE-Gastric studies with Arcus, and said its Phase 3 ASCENT-07 study of Trodelvy did not meet the primary endpoint of progression-free survival. Corporate updates included ground-breaking on a new technical development center in Foster City as part of a planned USD 32.0 billion U.S. investment through 2030, and the declaration (Feb. 10, 2026) of a quarterly dividend of USD 0.82 per share payable March 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000882095-26-000006), on February 24, 2026, and is solely responsible for the information contained therein.